Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
34 hedge funds and large institutions have $18.1M invested in Acorda Therapeutics in 2021 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 12 reducing their positions, and 6 closing their positions.
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
6% more funds holding
Funds holding: 32 → 34 (+2)
0% more capital invested
Capital invested by funds: $18M → $18.1M (+$52K)
16% less call options, than puts
Call options by funds: $749K | Put options by funds: $893K
50% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCA
Canyon Capital Advisors
Dallas,
Texas
|
+$859K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$298K |
| 3 |
Squarepoint
New York
|
+$215K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$195K |
| 5 |
State Street
Boston,
Massachusetts
|
+$138K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$498K |
| 2 |
Renaissance Technologies
New York
|
-$439K |
| 3 |
CCM
Chilton Capital Management
Houston,
Texas
|
-$311K |
| 4 |
QI
QS Investors
New York
|
-$247K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$210K |
ACOR Hedge Fund Activity: Q2 2021 in Review
34 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q2 2021, worth a combined $18.1M — up 0.29% from $18M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ACOR positions and 6 closed out — a net gain of 2 holders — while 6 added to existing stakes and 12 trimmed.
The largest buyer was Canyon Capital Advisors, adding an estimated $859K. The largest seller was Jacobs Levy Equity Management, cutting an estimated $498K.
- 34 institutional investors held Acorda Therapeutics (ACOR) as of Q2 2021, up from 32 in Q1 2021.
- Funds reported $18.1M of Acorda Therapeutics stock for Q2 2021, up 0.29% quarter-over-quarter.
- 8 funds opened new Acorda Therapeutics positions in Q2 2021 and 6 closed out, a net change of +2 holders.
- The largest Acorda Therapeutics buyer in Q2 2021 was Canyon Capital Advisors, an estimated $859K added.
- The largest Acorda Therapeutics seller in Q2 2021 was Jacobs Levy Equity Management, an estimated $498K sold.
Based on aggregated 13F filings for Q2 2021.